
BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

1,800+ experts will join the Global Bioeconomy Summit
First editions of the summit took place in Berlin in 2015 and 2018, this year it will be delivery fully virtually. The digital conference event...

Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Cancer antibody specialist BioInvent International AB has granted the exclusive rights to market its anti-FcγRIIB antibody, BI-1206, in China,...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Vifor Pharma in US$100m licence deal with Cara Therapeutics
Under the licence deal with the US company Cara Therapeutics Inc., Swiss Vifor Pharma has acquired the US commercialisation rights for intravenous...

Galecto raise US$85m in Nasdaq IPO
The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of...